New CCDS guidelines aim to standardize diagnosis in senior dogs: full analysis

A new consensus paper is trying to solve a problem many veterinarians already know well: canine cognitive dysfunction syndrome is common, clinically important, and still hard to diagnose with confidence. In the April 2026 issue of JAVMA, the Canine Cognitive Dysfunction Syndrome Working Group published diagnostic and monitoring guidelines that give the profession a shared definition of CCDS, a severity framework, and a staged diagnostic approach intended for both primary care and research use. (elib.tiho-hannover.de)

The push for formal criteria reflects a longstanding gap in practice. Prior research and reviews have noted that CCDS has been underdiagnosed and inconsistently managed, in part because there were no accepted consensus guidelines and because its signs overlap heavily with normal aging and other diseases common in senior dogs. NC State, which highlighted Natasha Olby’s role in convening the international group, said the effort grew out of years of work on measuring cognitive decline, mobility, sleep, and sensory change in aging dogs, and from the need to distinguish true neurodegenerative disease from the many other causes of behavior change in older patients. (pmc.ncbi.nlm.nih.gov)

The new guidance defines CCDS as a chronic, progressive, age-associated neurodegenerative syndrome that affects daily life through changes in the DISHAA domains: disorientation, social interaction, sleep disruption, house soiling, learning and memory, activity changes, and anxiety. The paper proposes three severity stages, from mild signs with preserved function to severe disease with overt deficits requiring comprehensive support. It also introduces two diagnostic levels. Level 1 relies on a consistent history of progressive DISHAA signs, physical, orthopedic, and neurologic examination, laboratory testing to identify alternate causes, and persistence of signs after relevant comorbidities are addressed. Level 2 adds MRI evidence of cortical atrophy and normal CSF cell counts. (elib.tiho-hannover.de)

For day-to-day practice, the monitoring recommendations may be the most actionable part of the paper. The working group says annual behavioral screening should begin at 7 years of age, with routine screening every 6 to 12 months thereafter to establish a baseline and identify early change. The authors recommend DISHAA as the most practical questionnaire for clinical use, though they also discuss CADES and CCDR. The paper notes that CADES may be more sensitive to mild change, while CCDR may be less susceptible to placebo effect and more stable over time, a distinction that could matter when practices choose tools for serial follow-up or clinical studies. (elib.tiho-hannover.de)

Industry and professional reaction has focused on accessibility for frontline clinicians. NC State said the guidelines were designed to be usable in primary care, where veterinarians are often the first to hear concerns from a pet parent about nighttime pacing, house-soiling, altered social behavior, or seeming disorientation. My Vet Candy’s coverage framed the paper as the first consensus-based roadmap for diagnosis, staging, and monitoring, and emphasized that comorbidities still need to be ruled out before a clinician can make even a Level 1 diagnosis. (news.cvm.ncsu.edu)

Why it matters: Standardized definitions could help reduce both under-recognition and overcalling. In practice, CCDS sits at the intersection of behavior, neurology, pain, sensory decline, internal medicine, and caregiver observation. A more structured framework may improve case workups, documentation, and longitudinal monitoring, especially in general practice settings that see large numbers of senior dogs but may not have easy access to advanced imaging. It also gives researchers and industry a more consistent language for enrollment criteria, endpoints, and future therapeutic studies. That matters because the field is already moving toward biomarker development, including work on blood-based approaches such as neurofilament light and machine learning-enhanced panels, but those tools still need validation for routine use. (elib.tiho-hannover.de)

There are also limits built into the new framework. The authors and related commentary make clear that these are early consensus standards, not the final word. MRI can help, but it adds cost and anesthetic considerations, and normal versus pathologic brain aging remains difficult to separate. Blood biomarkers and practical cognitive testing batteries are still in development, and the guidelines themselves are expected to evolve as larger datasets become available. In other words, the paper gives clinicians a clearer starting point, not a perfect diagnostic finish line. (elib.tiho-hannover.de)

What to watch: The next phase will likely center on validation, including how well the proposed stages and diagnostic levels perform in primary care, whether biomarker assays can support earlier detection, and how quickly screening workflows for dogs age 7 and older are adopted in everyday practice. (elib.tiho-hannover.de)